Patents Represented by Attorney Clark & Elbing LLP
  • Patent number: 8221381
    Abstract: The present invention provides a container system for releasably storing a substance. The container system includes a vial having a sample storage chamber and a piercing member for piercing a membrane in the lid, which membrane seals a substance within a reservoir in the lid until the membrane is pierced by the piercing member. The container system optionally includes a funnel. There is also provided a method and kit for use of such a container system.
    Type: Grant
    Filed: December 11, 2006
    Date of Patent: July 17, 2012
    Assignee: DNA Genotek Inc.
    Inventors: Rod Muir, Derek Kirkland, Ian Curry, Roy Sunstrum, Paul Lem, H. Chaim Birnboim
  • Patent number: 8216359
    Abstract: The invention features delayed-setting calcium phosphate pastes which are useful for the preparation of delivery vehicles for biologically active agents, useful for the treatment of orthopedic conditions and can be stored for long periods without prematurely setting.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: July 10, 2012
    Assignee: ETEX Corporation
    Inventors: Dosuk D. Lee, Youngmi M. Lee, legal representative, Aron D. Rosenberg, Laurent D. Gilles De Pelichy, Manish Sutaria, Aliassghar N. Tofighi
  • Patent number: 8216495
    Abstract: A method of preparation of a solid dispersion of a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer), such as Kollicoat IR with a BCS Class II drug or a BCS Class IV drug, whereby the method comprises: a) dissolving the polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) separately in a water/first alcohol mixture; and b) dissolving the BCS Class II drug or a BCS Class IV drug, in a mixture of a second alcohol with a non alcoholic organic solvent in which the compound has an high solubility; and c) mixing the both solutions to obtain a third solution with a total amount of solved solid of 1 to 15 g per 100 ml, and optionally having an acid, including inorganic acids including hydrohalic acids, e.g.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: July 10, 2012
    Assignee: Formac Pharmaceuticals N.V.
    Inventors: Sandrien Janssens, Guy Van Den Mooter
  • Patent number: 8217019
    Abstract: The present invention provides a vaccine containing a Sendai virus vector encoding a virus protein of an immunodeficiency virus. By intranasally administering a Sendai virus encoding a virus protein of an immunodeficiency virus to a macaque monkey, the present inventors have succeeded in efficiently inducing protective immunity against an immunodeficiency virus. As a result of intranasal inoculation of vaccine, expression of an antigen protein mediated by Sendai virus vector was detected in intranasal mucous membrane and local lymph nodes and antigen-specific cellular immune response was induced at a significant level. No pathological symptom by vaccination was observed. After vaccination, exposure of simian immunodeficiency virus was performed and the effect was examined. As a result, the amount of virus in plasma significantly decreased, compared with that of the control animal. The present invention provides a promising vaccine as an AIDS vaccine.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: July 10, 2012
    Assignees: DNAVEC Research Inc., Japan as Represented by the Director General of National Institute of Infectious Disease
    Inventors: Munehide Kano, Tetsuro Matano, Atsushi Kato, Yoshiyuki Nagai, Mamoru Hasegawa
  • Patent number: 8211461
    Abstract: The invention features compositions for administration of an oxidatively transformed carotenoid or a component thereof and methods of promoting weight gain and feed conversion efficiency therewith.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: July 3, 2012
    Assignee: Chemaphor Inc.
    Inventors: Graham William Burton, Janusz Daroszewski
  • Patent number: 8211868
    Abstract: The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 3, 2012
    Assignee: DNAVEC Research Inc.
    Inventors: Yoshikazu Yonemitsu, Katsuo Sueishi, Masayuki Fukumura, Xiaogang Hou, Mamoru Hasegawa, Hidenori Matsusaka, Hiroyuki Tsutsui
  • Patent number: 8207378
    Abstract: The invention relates to inhibitors of trypsin-like serine proteases of the general formula (I) which, as well as plasmin, also inhibit plasma kallikrien, and to their preparation and use as medicaments, preferably for treatment of blood loss, especially in the case of hyperfibrinolytic states, in organ transplants or heart surgery interventions, in particular with a cardiopulmonary bypass, or as a constituent of a fibrin adhesive.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: June 26, 2012
    Assignee: The Medicines Company (Leipzig) GmbH
    Inventors: Torsten Steinmetzer, Andrea Schweinitz, Joerg Stuerzebecher, Peter Steinmetzer, Anett Soeffing, Andreas Van De Locht, Silke Nicklisch, Claudia Reichelt, Friedrich-Alexander Ludwig, Alexander Schulze, Mohammed Daghisch, Jochen Heinicke
  • Patent number: 8203010
    Abstract: In general, the invention features compounds useful for the synthesis of analogs of halichondrin B, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: June 19, 2012
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Atsushi Endo, Charles E. Chase, Francis G. Fang
  • Patent number: 8203031
    Abstract: The invention relates to plants, especially transgenic plants, plant parts and plant cells overproducing a secretory phospholipase A2 protein (e.g. sPLA2-a or sPLA2-b) and having an enhanced resistance against a wide range of abiotic (e.g., against osmotic stress) and biotic stress (e.g., bacterial, or fungal infections) conditions as well as inducing early flowering. The invention also comprises nucleic acid sequences encoding a secretory phospholipase A2 or functional isoforms thereof and the use of such sequences for rendering plants resistant against abiotic and biotic stress conditions. The invention is useful for mitigating crop damages by a wide variety of pathogen infections and stress conditions and for accelerating flowering time.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: June 19, 2012
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Stephen Beungtae Ryu, Hyoung-Yool Lee, In-Whan Hwang, P. Palta Jiwan
  • Patent number: 8197430
    Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.
    Type: Grant
    Filed: November 10, 2000
    Date of Patent: June 12, 2012
    Assignee: Biopheresis Technologies, Inc.
    Inventor: M. Rigdon Lentz
  • Patent number: 8193321
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: June 5, 2012
    Assignee: Genentech, Inc.
    Inventors: Jenny M. Bostrom, Germaine Fuh
  • Patent number: 8193157
    Abstract: The field of the invention relates to the use of carbohydrate binding compounds as a medicine, their use to treat or prevent viral infections, their use to manufacture a medicine to treat or prevent viral infections and their use in a vaccination strategy. The present invention relates to the use of said compounds to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses having glycosilated envelop proteins such as Retroviridae (i.e. Lentivirinae), like HIV (human immunodeficiency virus), Flaviviridae, like HCV (hepatitis C virus), Hepadnaviridae, like HBV (hepatitis B virus), Coronaviridae, like SARS corona virus, and Orthomyxoviridae, like influenza A, B or C.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: June 5, 2012
    Assignees: K.U.Leuven Research & Development, Technische Universität Carolo Wilhelmina Zu Braunschweig
    Inventors: Jan Balzarini, Monika Mazik
  • Patent number: 8192937
    Abstract: The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: June 5, 2012
    Assignee: Exiqon A/S
    Inventors: Nana Jacobsen, Lars Kongsbak, Sakari Kauppinen, Søren Morgenthaler Echwald, Peter Mouritzen, Peter Stein Nielsen, Mikkel Nørholm
  • Patent number: 8188255
    Abstract: The invention provides new sequences for human microRNAs associated with cancer which may be used as molecular markers for cancer diagnostics or as therapeutic targets or agents.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: May 29, 2012
    Assignee: Exiqon A/S
    Inventors: Thomas Litman, Søren Møller, Søren Morgenthaler Echwald, Morten Lindow, Anders Martin Bøgild Jacobsen, Anders Stærmose Krogh, Sanne Nygaard, Rolf Søkilde
  • Patent number: 8188049
    Abstract: The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.
    Type: Grant
    Filed: October 8, 2007
    Date of Patent: May 29, 2012
    Assignee: Caregen Co., Ltd.
    Inventors: Yong-Ji Chung, Young Deug Kim, Eun Mi Kim, Jun Young Choi, Sang Su Song
  • Patent number: 8190248
    Abstract: Disclosed are devices and methods for detecting, preventing, and/or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: May 29, 2012
    Assignees: Louisiana Tech University Foundation, Inc., Board of Supervisors of Louisiana State University
    Inventors: Walter G. Besio, Mohammed Fasiuddin, Ravish Patwardhan
  • Patent number: 8185321
    Abstract: The present invention provides a method for configuring a pattern recognizer using versatile, readily available data, comprehensive protein data, and comprehensive chemical data, as well as a method for predicting an unknown interaction of a pair by using the pattern recognizer-configuring method. An interaction such as the coupling between a protein and a chemical is used as an index; at least one of four parameters is vectorized; a vector containing elements of the vector derived from each protein and elements of the vector derived from each chemical paired with the protein is created; and a support vector machine (SVM) is applied to this vector and trained to learn them, where the pattern recognizer is configured so as to discriminate between a class to which the first pair belong and a class to which the second pair belong.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: May 22, 2012
    Assignee: Keio University
    Inventors: Yasubumi Sakakibara, Nobuyoshi Nagamine
  • Patent number: 8178135
    Abstract: PROBLEMS TO BE SOLVED BY THE INVENTION To provide aqueous solutions of conophylline and/or conophyllidine; methods for purifying conophylline and/or conophyllidine from the aqueous solutions; methods for producing the aqueous solutions, water-soluble compositions containing conophylline and/or a conophyllidine useful for food compositions or pharmaceutical compositions or methods for preparing the same; as well as food compositions or pharmaceutical compositions containing the water-soluble compositions. MEANS OF SOLVING THE PROBLEMS It has been found that conophylline and/or conophyllidine can be efficiently extracted from a plant producing conophylline and/or conophyllidine with an acidic aqueous solution having a pH equal to or less than 4. The extract thus obtained, i.e., aqueous solution of conophylline, and/or conophyllidine is useful for production of, for instance, food compositions, pharmaceutical compositions, etc.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: May 15, 2012
    Assignee: Keio University
    Inventors: Kazuo Umezawa, Mikio Fujii
  • Patent number: 8177565
    Abstract: The invention features an electrical connection apparatus capable of operatively attaching to an electrical appliance or electrical socket. The apparatus also includes at least two electrical connections which can communicate with each other to allow the flow of electrical charge therebetween. The apparatus can also be arranged to allow relative movement of the at least first and/or second electrical connection between a first position, wherein electrical charge can flow therebetween, and a second position, wherein the flow of electrical charge is prevented. The relative movement can take place over a pre-determined time period following actuation to provide a timing mechanism for the apparatus.
    Type: Grant
    Filed: October 5, 2007
    Date of Patent: May 15, 2012
    Assignee: Logicor Limited
    Inventor: David Bowen
  • Patent number: RE43467
    Abstract: The present invention features a novel combination therapy useful in the treatment of autoimmune disease that increases or maintains the number of functional cells of a predetermined type in a mammal by killing or inactivating autoimmune cells and re-educating the host immune system.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: June 12, 2012
    Assignee: The General Hospital Corporation
    Inventor: Denise Faustman